Bones and Crohn’s: No benefit of adding sodium fluoride or ibandronate to calcium and vitamin D

Table 1 Baseline characteristics (mean ± SD) n (%)

	Group A calcium/vitamin D	Group B0/1 + sodium fluoride	Group C0/1 + ibandronate
No. of patients	32	62	54
Male/female	14/18	29/33	27/27
Age (yr)	33.8 ± 9.76	35.7 ± 12.8	36.8 ± 13.1
Duration of disease (yr)	7.4 ± 1.7	9.4 ± 2.1	8.1 ± 1.9
Smoking	13 (40.6)	23 (37.1)	19 (35.2)
Postmenopausal	0	2	1
Extent of disease
Ileal disease	11 (34.4)	20 (32.3)	21 (38.9)
Colonic disease	5 (15.6)	8 (12.9)	7 (13)
Ileocolonic disease	16 (50.0)	34 (54.8)	26 (48.1)
Bowel resection
No bowel resection	18 (56.2)	39 (62.9)	29 (53.7)
Ileal resection	8 (25.0)	12 (19.4)	14 (25.9)
Colonic resection	2 (6.2)	5 (8.1)	4 (7.4)
Ileocolonic resection	4 (12.6)	6 (9.7)	7 (13)
Patients with bowel resection during study	4	6	5
Use of corticosteroids
No previous use	3 (9.4)	6 (9.7)	6 (11.1)
Cumulative dose < 10 g	22 (68.8)	36 (58.1)	34 (63)
Cumulative dose > 10 g	7 (21.8)	28 (32.2)	14 (25.9)
Body weight (kg)	69.4 ± 15.51	63.71 ± 11.9	64.8 ± 13.91
Body height (cm)	172 ± 7.63	170 ± 8.8	170 ± 9.0
BMI (kg/m2)	23.54 ± 5.34	22.01 ± 3.6	22. 4 ± 3.92
CDAI	141.5 ± 100.96	145 ± 95.5	135.9 ± 85.03
T-score spine	-1.57 ± 0.31	-1.82 ± 0.75	-1.89 ± 0.71
BMD spine (g/cm2)	0.90 ± 0.04	0.87 ± 0.09	0.85 ± 0.08
Pre-existing vertebral fractures1	6 (22.2) of patients with 10 fractures	9 (19.2) of patients with 18 fractures	14 (28.6) of patients with 28 fractures

¹Intention to treat (ITT) analysis. BMI: Body mass index; CDAI: Crohn’s disease activity index; BMD: Bone mineral density.